Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics

Current Pharmaceutical Design

Volumn 11, Issue 22, 2005, Pages 2889-2907

  Wang, Hui ^a,b   Rayburn, Elizabeth ^a   Zhang, Ruiwen ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL DNA; CANCER VACCINE; CYCLOPHOSPHAMIDE; DEOXYCYTIDYLDEOXYGUANOSINE DINUCLEOTIDE DERIVATIVE; DNA VACCINE; DOCETAXEL; DOXORUBICIN; LIVE VACCINE; MITOMYCIN; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TAXANE DERIVATIVE; TOLL LIKE RECEPTOR 9; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL TYPE; CLINICAL TRIAL; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INNATE IMMUNITY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MONOCYTE; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; DEOXYCYTOSINE NUCLEOTIDES; DEOXYGUANOSINE; DRUG DESIGN; HUMANS; IMMUNE SYSTEM; NEOPLASMS;

EID: 22944457857     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054546707     Document Type: Review

References (155)

1. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64: 529-64.
2. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72: 955-62.
3. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O, Tokunaga T. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 1992; 148: 4072-6.
4. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991; 147: 1759-64.
5. Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics. Curr Cancer Drug Targets 2001; 1: 177-96.
6. Agrawal S, Kandimalla ER. Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets 2001; 1: 197-209.
7. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
8. Zamecnik P. Background of the antisense oligonucleotide approach to chemotherapy. Antisense Nucleic Acid Drug Dev 1997; 7: 199-202.
9. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci USA 1997; 94: 2620-5.
10. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 1999; 96: 13989-94.
11. Goel S, Desai K, Bulgaru A, Fields A, Goldberg G, Agrawal S, et al. A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin Cancer Res 2003; 9: 4069-76.
12. Mani S, Goel S, Nesterova M, Martin RM, Grindel JM, Rothenberg ML, et al. Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I. Ann NY Acad Sci 2003; 1002: 252-62.
13. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9.
14. Klinman DM, Yi AK, Beaucage SL, Conover J, Kreig AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93: 2879-83.
15. Shoda LK, Kegerreis KA, Suarez CE, Mwangi W, Knowles DP, Brown WC. Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages. J Leukoc Biol 200; 70: 103-12.
16. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, et al. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev 2001; 11: 333-40.
17. Hacker H, Mischak H, Hacker G, Eser S, Prenzel N, Ullrich A, et al. Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. EMBO J 1999; 18: 6973-82.
18. Kandimalla ER, Yu D, Agrawal S. Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr Opin Mol Ther 2002; 4: 122-9.
19. Sabroe I, Parker LC, Wilson AG, Whyte MK, Dower SK. Toll-like receptors: their role in allergy and non-allergic inflammatory disease. Clin Exp Allergy 2002; 32: 984-9.
20. Van Uden J, Raz E. Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol 1999; 104: 902-10.
21. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998; 160: 3627-30.
22. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamraz SS, et al. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 2000; 18: 1920-4.
23. Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001; 19: 2862-77.
24. Agrawal S, Kandimalla ER. Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA. Ann N Y Acad Sci 2003; 1002: 30-42.
25. Kandimalla ER, Bhagat L, Zhu FG, Yu D, Cong YP, Wang D, et al. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci USA 2003; 100: 14303-8.
26. Cong YP, Song SS, Bhagat L, Pandey RK, Yu D, Kandimalla ER, et al. Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Biochem Biophys Res Commun 2003; 310: 1133-9.
27. Kandimalla ER, Bhagat L, Cong YP, Pandey RK, Yu D, Zhao Q, et al. Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem Biophys Res Commun 2003; 306: 948-53.
28. Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, et al. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res 2003; 31: 2393-400.
29. Agrawal DK, Edwan J, Kandimalla ER, Yu D, Bhagat L, Wang D, et al. Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. Int Immunopharmacol 2004; 4: 127-38.
30. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett 2001; 11: 2263-7.
31. Agrawal S, Kandimalla ER. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med 2002; 8: 114-21.
32. Kandimalla ER, Yu D, Zhao Q, Agrawal S. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg Med Chem 2001; 9: 807-13.
33. Leitner WW, Hammerl P, Thalhamer J. Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants. Curr Pharm Des 2001; 7: 1641-67.
34. Krieg AM. From A to Z on CpG. Trends Immunol 2002; 23: 64-5.
35. Carpentier AF, Auf G, Delattre JY. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci 2003; 8: e115-27.
36. Wooldridge JE, Weiner GJ. CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr Opin Oncol 2003; 15: 440-5.
37. Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 2003; 109: 64-71.
38. Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs 2003; 4: 686-90.
39. Uhlmann E, Vollmer J. Recent advances in the development of immunostimulatory oligonucleotides. Curr Opin Drug Discov Devel 2003; 6: 204-17.
40. Okamoto M, Sato M. Toll-like receptor signaling in anti-cancer immunity. J Med Invest 2003; 50: 9-24.
41. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004; 6: 88-95.
42. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004; 34: 251-62.
43. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 2004; 16: 17-22.
44. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999; 73: 329-68.
45. Han J, Zhu Z, Hsu C, Finley WH. Selection of antisense oligonucleotides on the basis of genomic frequency of the target sequence. Antisense Res Dev 1994; 4: 53-65.
46. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, et al. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA 1998; 95: 12631-6.
47. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human hemologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-7.
48. Goto M, Washio T, Tomita M. Causal analysis of CpG suppression in the Mycoplasma genome. Microb Comp Genomics 2000; 5: 51-8.
49. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-5.
50. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, et al. Cutting edge: Role of Toll like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001; 167: 3555-8.
51. Zhao Z, Matson S, Herrera CJ, Fisher E, Yu H, Krieg AM. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev 1993; 3: 53-66.
52. Boggs RT, McGraw K, Condon T, Flournoy S, Villiet P, Bennet CF, et al. Characterization and modulation of immune stimulation by modified oligonucleotides. Antisense Nucleic Acid Drug Dev 1997; 7: 461-71.
53. Krieg AM. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol 1996; 4: 73-6.
54. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000; 164: 944-53.
55. Hartmann G, Weiner GJ, Krieg AM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A 1999; 96: 9305-10.
56. Bhagat L, Zhu FG, Yu D, Tang J, Wang H, Kandimalla ER. CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochem Biophys Res Commun 2003; 300: 853-61.
57. Yi AK, Hornbeck P, Lafrenz DE, Krieg AM. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol 1996; 157: 4918-25.
58. Iho S, Yamamoto T, Takahashi T, Yamamoto S. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J Immunol 1999; 163: 3642-52.
59. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998; 188: 2335-42.
60. Lipford GB, Sparwasser T, Bauer M, Zimmermann S, Koch ES, Heeg K, et al. Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol 1997; 27: 3420-6.
61. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 3388-93.
62. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28: 2045-54.
63. Kadowaki N, He S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-70.
64. Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP, Wagner H, et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol 2001; 166: 5000-7.
65. Ban E, Dupce L, Hermann E, Rohn W, Vendeville C, Quatannens B, et al. CpG motifs induce Langerhans cell migration in vivo. Int Immunol 2000; 12: 737-45.
66. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999; 189: 169-78.
67. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849-54.
68. Chu RS, Askew D, Harding CV. CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function. Curr Top Microbiol Immunol 2000; 247: 199-210.
69. Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, et al. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 2000; 165: 6244-51.
70. Chu RS, Askew D, Noss EH, Tobian A, Krieg AM, Harding CV. CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol 1999; 163: 1188-94.
71. Dalpke AH, Opper S, Zimmermann S, Heeg K. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J Immunol 2001; 166: 7082-9.
72. Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, et al. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002; 32: 3235-45.
73. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, et al. Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol 2000; 165: 6278-86.
74. Kemp TJ, Elzey BD, Griffith TS. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003; 171: 212-8.
75. Stoiber D, Kovarik P, Cohney S, Johnston JA, Steinlein P, Decker T. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J Immunol 1999; 163: 2640-7.
76. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 2001; 166: 2372-7.
77. Liang H, Nishioka Yuichi, Reich CF, Pisetsky DS, Lipsky PE. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest 1996; 98: 1119-1129.
78. Yi AK and Krieg AM. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol 1998; 161: 4493-7.
79. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2000; 69: 81-8.
80. Yi AK, Yoon JG, Krieg AM. Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol 2003; 15: 577-91.
81. Jung J, Yi AK, Zhang X, Choe J, Li L, Choi YS. Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. Immunol 2002; 169: 2368-73.
82. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-5.
83. Chace JH, Hooker NA, Mildenstein KL, Krieg AM, Cowdery JS. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol 199; 84: 185-93.
84. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 1999; 59: 5429-32.
85. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ. NK- and CD8 (+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 2001; 167: 5247-53.
86. He H, Crippen TL, Farnell MB, Kogut MH. Identification of CpG oligodeoxynucleotide motifs that stimulate nitric oxide and cytokine production in avian macrophage and peripheral blood mononuclear cells. Dev Comp Immunol 2003; 27: 621-7.
87. Utaisincharon P, Anuntagool N, Chaisuriya P, Pichyangkul S, Sirisinha S. CpG ODN activates NO and iNOS production in mouse macrophage cell line (RAW 264.7). Clin Exp Immunol 2002; 128: 467-73.
88. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 2001; 7: 3540-3.
89. Shoda LK, Kegerreis KA, Suarez CE, Mwangi W, Knowles DP, Brown WC. Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages. J Leukoc Biol 2001; 70: 103-12.
90. Hartmann G, Krieg AM. CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther 1999; 6: 893-903.
91. Pichyangkul S, Yongvanitchit K, Kum-arb U, Krieg AM, Heppner DG, Walsh DS. Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. J Immunol Methods 2001; 247: 83-94.
92. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623-31.
93. Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Rocken M. Egeter. Cancer Res 2000; 60: 1515-20.
94. Baines J and Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003; 9: 2693-700.
95. Underhill DM and Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002; 14: 103-10.
96. Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, et al. Activation of NF-kB by nontypeable Hemophilus influenzae is mediated by Toll-like receptor 2-TAK1-dependent NIK-IKKa/b-IkBa and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci USA 2001; 98: 8774-9.
97. Jiang Z, Ninomiya-Tsuji J, Qian Y, Matsumoto K, Lib X. Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol 2002; 22: 7158-67.
98. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med 2000; 192: 595-600.
99. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002; 32: 1958-68.
100. Bowman CC, Rasley A, Tranguch SL, Marriot, I. Cultured astrocytes express toll-like receptors for bacterial products. Glia 2003; 43: 281-91.
101. Zarember KA and Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168: 554-61.
102. Chu WM, Gong X, Li ZW, Takabayashi K, Ouyang HH, Chen Y, et al. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell 2000 103: 909-18.
103. Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, et al. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med 2002; 196: 269-74.
104. Verthelyi D, Zeuner RA. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol 2003; 24: 519-22.
105. Kandimalla ER, Zhu FG, Bhagat L, Yu D, Agrawal S. Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs. Biochem Soc Trans 2003; 31: 654-8.
106. Zhao Q, Temsamani J, Iadarola PL, Jiang Z, Agrawal S. Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol 1996; 51: 173-82.
107. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem 2001; 9: 2803-8.
108. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Immunostimulatory properties of phosphorothioate CpG DNA containing both 3′-5′- and 2′-5′-internucleotide linkages. Nucleic Acids Res 2002; 30: 1613-9.
109. 106. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett 2001; 11: 2263-7.
110. Yu D, Kandimalla ER, Cong Y, Tang J, Tang JY, Zhao Q, Agrawal S. Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: role of nucleosides in the flanking sequences. J Med Chem 2002; 45: 4540-8.
111. Yu D, Kandimalla ER, Zhao Q, Bhagat L, Cong Y, Agrawal S. Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorg Med Chem 2003; 11: 459-64.
112. Yu D, Zhao Q, Kandimalla ER, Agrawal S. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett 2000 10: 2585-8.
113. Kandimalla ER, Bhagat L, Yu D, Cong Y, Tang J, Agrawal S. Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconj Chem 2002 13: 966-974.
114. Yu D, Kandimalla ER, Bhagat L, Tang J, Cong Y, Tang J, et al. 'Immunomers' - novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nuc Acids Res 2002; 30: 4460-9.
115. Yu D, Zhu F, Bhagat L, Wang H, Kandimalla ER, Zhang R, et al. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Comm 2002; 297: 83-90.
116. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998; 161: 2428-34.
117. Oxenius A, Martinic MM, Hengartner H, Klenerman P. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol 1999; 73: 4120-6.
118. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999; 162: 2291-8.
119. Klinman DM, Verthelyi D, Takeshita F, Ishii KJ. Immune recognition of foreign DNA: a cure for bioterrorism? Immunity 1999; 11: 123-9.
120. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun 2001; 69: 1643-9.
121. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol 2000; 165: 4537-43.
122. Williamson ED, Bennett AM, Perkins SD, Beedham RJ, Miller J, Baillie LW. Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine 2002; 20: 2933-41.
123. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998; 160: 3627-30.
124. Ito S, Ishii KJ, Shirota H, Klinman DM. CpG Oligodeoxynucleotides Improve the Survival of Pregnant and Fetal Mice following Listeria monocytogenes Infection. Infect Immun 2004; 72: 3543-8.
125. Sparwasser T, Hultner L, Koch ES, Luz A, Lipford GB, Wagner H. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol 1999; 162: 2368-74.
126. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 2001; 3: 15-24.
127. Stevceva L, Strober W. Mucosal HIV vaccines: where are we now? Curr HIV Res 2004; 2: 1-10.
128. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release 2004; 97: 1-17.
129. Jones TR, Obaldia N 3rd, Gramzinski RA, Charoenvit Y, Kolodny N, Kitov S, et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 1999; 17: 3065-71.
130. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998; 161: 4463-6.
131. McCluskie MJ, Wen YM, Di Q, Davis HL. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol 1998; 11: 245-52.
132. McCluskie MJ, Weeratna RD. Novel adjuvant systems. Curr Drug Targets Infect Disord 2001; 1: 263-71.
133. McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol 2001; 21: 103-20.
134. Jenkins M, Parker C, Tuo W, Vinyard B, Dubey JP. Inclusion of CpG adjuvant with plasmid DNA coding for NcGRA7 improves protection against congenital neosporosis. Infect Immun 2004; 72: 1817-9.
135. Karin N. Induction of protective therapy for autoimmune diseases by targeted DNA vaccines encoding pro-inflammatory cytokines and chemokines. Curr Opin Mol Ther 2004; 6: 27-33.
136. Peng HJ, Tsai LC, Su SN, Chang ZN, Shen HD, Chao PL, et al. Comparison of different adjuvants of protein and DNA vaccination for the prophylaxis of IgE antibody formation. Vaccine 2004; 22: 755-61.
137. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998; 161: 7054-62.
138. Hussain I, Kline JN. CpG oligodeoxynucleotides in asthma. Curr Opin Investig Drugs 2001; 2: 914-8.
139. Jain VV, Kitagaki K, Kline JN. CpG DNA and immunotherapy of allergic airway diseases. Clin Exp Allergy 2003; 33: 1330-5.
140. Peng Z, Wang H, Mao X, HayGlass KT, Simons FE. CpG oligodeoxynucleotide vaccination suppresses IgE induction but may fail to down-regulate ongoing IgE responses in mice. Int Immunol 2001; 13: 3-11
141. Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol 2000; 164: 5575-82.
142. Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK, Jain V, Businga TR. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol 1999; 104: 1258-64.
143. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, et al. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169: 3892-9.
144. Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 2003; 171: 3941-6.
145. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol 2004; 24: 901-8.
146. Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999-1006.
147. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169: 350-8.
148. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997; 89: 2994-8.
149. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9: 3105-14.
150. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, et al. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004; 40: 1275-81.
151. Ioannou XP, Griebel P, Mena A, Gomis SM, Godson DL, Mutwiri G, et al. Safety of CpG oligodeoxynucleotides in veterinary species. Antisense Nucleic Acid Drug Dev 2003; 13: 157-67.
152. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004; 10: 187-92.
153. Baumgart DC, Dignass AU. Current biological therapies for inflammatory bowel disease. Curr Pharm Design 2004; 10(32): 4127-47.
154. McGuire JJ. Anticancer antifolates: current status and future directions. Curr Pharm Design 2003; 9(31): 2593-613.
155. Stewart JM. Bradykinin antagonists as anti-cancer agents. Curr Pharm Design 2003; 9(25): 2036-42.